6 , 2011 / PRNewswire / -- Generex Biotechnology Corporation ( www.generex.com ) ( OTC Bulletin Board : GNBT ) , together with its wholly-owned immunotherapeutic vaccines subsidiary , Antigen Express , Inc . ( www.antigenexpress.com ) , and RXi Pharmaceuticals Corporation ( www.rxipharma.com ) ( NasdaqCM : RXII ) , a recognized leader in RNAi-based therapeutics , today announced that they have obtained positive early research data from their collaboration to explore the use of RXi 's RNAi technology to develop proprietary vaccine formulations for active immunotherapy .